ARLINGTON, Va., March 10 /PRNewswire/ -- BioInformatics, LLC announces availability of its newest report, Prospering in a Down Market: Strategies for Life Science Suppliers. In this report, BioInformatics, LLC (www.gene2drug.com), the premier research and advisory firm serving the life science market, provides hard data and analysis that supports fast -- and strategic -- decision-making for life science suppliers. BioInformatics, LLC fielded a detailed 45-question survey to more than 500 senior scientists and lab managers working in universities, pharmaceutical and biotechnology companies.
The report is available at pre-release pricing for the remainder of this week, until March 15, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect next Monday, March 16, 2009.
Providing a roadmap for the life science supplier, this study compares and contrasts FY2008 (actual) and FY2009 (projected) lab budgets, revealing anticipated trends and changes. 14 product categories are examined using multiple variables, including current suppliers and projected expenditures through FY2010. The following companies were chosen most frequently as the primary supplier in at least one of the product categories:
Affymetrix (Nasdaq: AFFX) BD BioSciences (NYSE: BDX) Bio-Rad Laboratories (NYSE: BIO) Dell Computer Corp (Nasdaq: DELL) Carl Zeiss Life Technologies (Nasdaq: '/>"/>
|SOURCE BioInformatics, LLC|
Copyright©2009 PR Newswire.
All rights reserved